RGN Stock Chart & Stats
€150.20
-€1.35(-1.17%)
At close: 4:00 PM EDT
€150.20
-€1.35(-1.17%)
Day’s Range― - ―
52-Week Range€86.32 - €170.65
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.03B
Enterprise Value€10.70B
Total Cash (Recent Filing)€862.98M
Total Debt (Recent Filing)€692.24M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Feb 24, 2027EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding63,490,364
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€187.75Price Target Upside25.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.85
Revenue Forecast (FY)€755.22M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelValidated consumables and replaceable process components can create repeat purchasing and customer stickiness. Revalidation requirements make switching less attractive, supporting recurring revenue, durable account relationships, and more predictable demand as biologics manufacturing expands.
Cash Generation And Balance SheetStrong operating and free cash flow provide internal funding for investment, acquisitions, and debt service. Combined with moderate leverage and substantial equity, this gives Repligen financial flexibility to pursue growth while absorbing normal business volatility.
Diversified Growth PlatformGrowth across bioprocessing franchises and the completed BioLife acquisition broadens Repligen’s exposure to cell therapy and other expanding modalities. The combination of organic growth and complementary capabilities supports a larger, more diversified long-term revenue base.
Bears Say
Weak Net ProfitabilityNegative net income reduces earnings quality and makes reported profitability less reliable despite positive operating cash flow and EBITDA. Margins below prior peaks indicate that the company has not yet fully restored its former earnings power or operating efficiency.
Filtration And Equipment HeadwindsFiltration weakness directly pressures an established product franchise, while delayed equipment conversion pushes recognized revenue into later periods. These issues can make near-term growth uneven and increase reliance on stronger chromatography, protein, and analytics performance.
Convertible Financing And DilutionThe refinancing extends maturities and raises cash, but the large convertible issuance adds future dilution risk if conversion occurs. It also increases the complexity of capital allocation and may constrain per-share benefits from otherwise successful operating growth.
Repligen News
RGN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was €86.32 and its highest was €170.65 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is €10.03B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Feb 24, 2027 which is in 115 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Oct 27, 2026. The company reported €0.473 earnings per share for the quarter, beating the consensus estimate of €0.413 by €0.06.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.47.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 63,490,364 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of €0.473 in its last earnings report, beating expectations of €0.413. Following the earnings report the stock price went down -2.655%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in DE:RGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€187.75 (25.00% Upside)
€187.75 (25.00% Upside)
Blogger Sentiment
Neutral
DE:RGN Sentiment 57%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.39%
12-Months-Change
Fundamentals
Return on Equity
-0.56%
Trailing 12-Months
Asset Growth
0.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Repligen Corp
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGN Company Deck
RGN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Repligen reported record revenue, double-digit organic growth, operating margin expansion, higher full-year guidance, strong demand in chromatography, proteins, analytics, China, services, and capital equipment orders, and encouraging early progress integrating BioLife. The company acknowledged meaningful challenges, including an 11% filtration decline, delayed equipment revenue conversion, a 30-basis-point gross margin decline, customer decision delays, and on-shoring projects running 9 to 12 months behind expectations, but management expressed confidence in the 2027 outlook and continued market-share and growth opportunities.View all DE:RGN earnings summariesRGN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGN Stock 12 Month Forecast
Average Price Target
€187.75
▲(25.00% Upside)